Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28909603 | 1.00 | HCRTR2 (0.47) | HCRTR2MPOMEN1KMT2ACHRM5 | |
| SCHEMBL28540055 | 1.00 | HCRTR2 (0.47) | HCRTR2MPOMEN1KMT2ACHRM5 | |
| SCHEMBL17345636 | 0.95 | MPO (0.48) | HCRTR2MPOMEN1KMT2ACHRM5 | |
| SCHEMBL21516391 | 0.93 | MPO (0.47) | HCRTR2MPOMEN1KMT2ACHRNB2 | |
| SCHEMBL29456377 | 0.93 | MPO (0.47) | HCRTR2MPOMEN1KMT2ACHRNB2 | |
| Hydrochloric Acid SCHEMBL21491396 | 0.92 | MPO (0.46) | HCRTR2MPOMEN1KMT2ACHRNB2 | |
| SCHEMBL28526259 | 0.87 | MEN1 (0.40) | HCRTR2MPOMEN1KMT2ACHRM5 | |
| SCHEMBL28533797 | 0.87 | MEN1 (0.40) | HCRTR2MPOMEN1KMT2ACHRM5 | |
| SCHEMBL28527483 | 0.84 | MPO (0.38) | HCRTR2MPOMEN1KMT2ACHRM5 | |
| SCHEMBL23323082 | 0.83 | MPO (0.41) | MPOMEN1KMT2ACHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-20240376104-A1 | Bcl-2 Inhibitors | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| US-12077536-B2 | BCL-2 inhibitors | BEIGENE, LTD. (KY) | 2024-09-03 | — | — | US | disclosed |
| CN-117683029-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117430601-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-112437772-B | Bcl-2 inhibitors | 百济神州有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
| US-11420968-B2 | Bcl-2 inhibitors | BEIGENE, LTD. (KY) | 2022-08-23 | — | — | US | disclosed |
| CN-112437772-A | Bcl-2 inhibitors | 百济神州有限公司 | 2021-03-02 | — | — | CN | disclosed |
| EP-3444031-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2019-02-20 | — | — | EP | disclosed |
| EP-3068391-B1 | ARYL LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME (US) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | HCRTR2 2324/4885MPO 1033/4885MEN1 3803/4885 |
| US-11420968-B2 | Bcl-2 inhibitors | BCL2, BCL2L1, BCL2L2 | HCRTR2 2324/4885MPO 1033/4885MEN1 3803/4885 |
| US-12077536-B2 | BCL-2 inhibitors | BCL2, BCL2L1, BCL2L2 | HCRTR2 2324/4885MPO 1033/4885MEN1 3803/4885 |
| US-20240376104-A1 | Bcl-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | HCRTR2 2324/4885MPO 1033/4885MEN1 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.